Larimar Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Larimar Therapeutics

08/05/2023 19:30

* Larimar Therapeutics Inc  LRMR.OQ   LRMR.O  is expected
to show
no change in quarterly revenue when it reports  results on May
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Larimar
Therapeutics Inc
is for a loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Larimar
Therapeutics Inc is $13​, above​ its last closing price
of $4.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.22       -0.27      -0.21     Beat    22.9
 Sep. 30 2022  -0.30       -0.42      -0.37     Beat    11.9
 Jun. 30 2022  -0.49       -0.57      -0.47     Beat    18​
 Mar. 31 2022  -0.51       -0.51      -0.49     Beat    3.9
 ​​Dec.        -0.76       -0.72      -0.50     Beat    30.2
 31 2021                                                
 Sep. 30 2021  -0.64       -0.64      -0.92     Missed  -43​
 Jun. 30 2021  -0.74       -0.75      -0.79     Missed  -5.8
 Mar. 31 2021  -0.86       -0.86      -0.76     Beat    12.1
 This summary was machine generated May 8 at 18:30 GMT.  All
figures in US dollars  unless otherwise stated